UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Amendment Number 1
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 8, 2004
RENAL CARE GROUP, INC.
| Delaware | 0-27640 | 62-1622383 | ||
| (State or Other Jurisdiction | (Commission File Number) | (I.R.S. Employer | ||
| of Incorporation) | Identification No.) |
2525 West End Avenue
Suite 600
Nashville, TN 37203
(Address of Principal Executive Offices, including Zip Code)
(615) 345-5500
(Registrant’s telephone number, including area code)
N/A
| EXPLANATORY NOTE | ||||||||
| Item 7. Financial Statements and Exhibits. | ||||||||
| Item 9. Regulation FD Disclosure. | ||||||||
| SIGNATURES | ||||||||
| INDEX TO EXHIBITS | ||||||||
| Exhibit 99.1 | ||||||||
| EX-99.1 PAGE 23 TO SLIDE PRESENTATION | ||||||||
EXPLANATORY NOTE
Renal Care Group, Inc. is hereby amending its current report on Form 8-K as filed with the Securities and Exchange Commission on June 9, 2004, to replace page 23 of Exhibit 99.1 to that Form 8-K. The corporate objective for earnings per share shown in the original exhibit did not show a revision to give effect to the three for two stock split that was effective on May 24, 2004. Attached as Exhibit 99.1 to this current report on Form 8-K/A is a revised page 23 showing the correct corporate objective for earnings per share. Except for this new page 23, which replaces the original page 23 in its entirety, no other information in our original current report on Form 8-K is amended by this amendment.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
99.1
|
Page 23 to slide presentation to be used at analyst and shareholder meetings between June 9, 2004 and June 30, 2004. |
Item 9. Regulation FD Disclosure.
Beginning on or about June 9, 2004 and continuing through no later than June 30, 2004, one or more officers of Registrant will make slide presentations to a number of shareholders of Registrant, as well as potential investors and investment analysts. The slide presentation contains, among other things, forward-looking information about Registrant and its business. The slides that Registrant will use in these presentations were attached to our original current report on Form 8-K as Exhibit 99.1, a revised page 23 to this slide presentation is attached to this amendment number 1 to current report on Form 8-K/A.
Certain statements in the slide presentation, specifically including the corporate objectives outlined in the attached page 23, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management’s expectations and are based on currently available information. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Renal Care Group to differ materially from those expressed or implied by the forward-looking statements, including risks related to: the integration of acquired businesses; substantial leverage; compliance with health care and other applicable laws; changes in the Medicare and Medicaid programs; payment reductions by private insurers, hospitals or managed care organizations; reductions in reimbursement for the drug Epogen; increases in the price of Epogen or shortages of Epogen; competition; and changes in the health care delivery, financing or reimbursement systems. These and other factors affecting the company are discussed in more detail in Renal Care Group’s reports filed with the Securities and Exchange Commission, including without limitation, Renal Care Group’s annual report on Form 10-K for the year ended December 31, 2003, its current report on Form 8-K filed with the SEC on April 19, 2004 and its quarterly report on Form 10-Q for the quarter ended March 31, 2004.
The information in this current report on Form 8-K is furnished pursuant to Item 9 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This current report on Form 8-K will not be deemed an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD. The Registrant undertakes no duty to update the information in this report and warns readers that the information included in this report will become stale after June 30, 2004.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| RENAL CARE GROUP, INC. | |||
By:
|
/s/ David M. Dill | ||
Name:
|
David M. Dill | ||
Title:
|
Chief Financial Officer | ||
Date: June 9, 2004
3
INDEX TO EXHIBITS
| Exhibit Number |
Description of Exhibits |
|
99.1
|
Page 23 to slide presentation to be used at analyst and shareholder meetings between June 9, 2004 and June 30, 2004 |
4